Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21146835 | 0.83 | DPP4 (0.36) | DPP4 | |
| SCHEMBL10121282 | 0.79 | ALDH1A1 (0.38) | DPP4KDM4ENPC1MAPTHTT | |
| SCHEMBL10151282 | 0.79 | DPP4 (0.36) | DPP4KDM4ENPC1MAPTHTT | |
| SCHEMBL19229600 | 0.79 | DPP4 (0.43) | DPP4 | |
| SCHEMBL13145489 | 0.77 | TSHR (0.50) | KDM4E | |
| SCHEMBL10150977 | 0.77 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL11929163 | 0.74 | ALDH1A1 (0.42) | — | |
| SCHEMBL19679946 | 0.73 | ALOX5 (0.39) | — | |
| SCHEMBL20412243 | 0.72 | — | — | |
| SCHEMBL2737323 | 0.71 | WRN (0.41) | KDM4ENPC1MAPTRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172299-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172299-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | TUBB6, TUBB3, TUBB2A | DPP4 919/4885KDM4E 3706/4885NPC1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.